Patrik Keringer Selected Research

YM 022

1/2022

The hyperthermic effect of central cholecystokinin is mediated by the cyclooxygenase-2 pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patrik Keringer Research Topics

Disease

3	Fever (Fevers) 01/2022 - 01/2018
2	Hypothermia 04/2024 - 09/2021
2	Hyperthermia 01/2023 - 01/2022
2	Inflammation (Inflammations) 01/2022 - 01/2018
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Atherosclerosis 01/2022
1	Pain (Aches) 12/2020

Drug/Important Bio-Agent (IBA)

3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2022 - 01/2018
2	LipopolysaccharidesIBA 01/2022 - 01/2018
2	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 01/2019 - 01/2018
1	Ammonium Chloride (Sal Ammoniac)FDA Link 04/2024
1	YM 022IBA 01/2022
1	Cholecystokinin (Pancreozymin)IBA 01/2022
1	CholesterolIBA 01/2022
1	EndotoxinsIBA 01/2022
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2022
1	Cholecystokinin B ReceptorIBA 01/2022
1	sodium sulfideIBA 09/2021
1	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 09/2021
1	GYY 4137IBA 09/2021
1	EnzymesIBA 12/2020
1	GalaninIBA 12/2020
1	CytokinesIBA 01/2018
1	Dinoprostone (PGE2)FDA Link 01/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018

Therapy/Procedure

2	Induced Hyperthermia (Thermotherapy) 01/2023 - 01/2022
1	Vagotomy 01/2023
1	Meniscectomy 12/2020